Athens Medical Center S.A.

The Oncology program at Athens Medical Center S.A. in Thessaloniki focuses on Neoplasms, especially cancers of the lung, breast, melanoma, and colorectal cancer. The trials are largely designed to test new treatment approaches, compare them with current standards of care, and help reduce the risk of recurrence after surgery or earlier treatment.

• Research in non-small cell lung cancer and small cell lung cancer, including studies aimed at improving survival and disease control
• Trials in melanoma and cutaneous squamous cell carcinoma that explore ways to prevent cancer from returning after resection
• Studies in breast cancer and advanced colorectal cancer evaluating new options for patients at higher risk of recurrence
• Comparisons of newer immunotherapy and targeted therapy combinations against established treatments

Overall, the site is contributing to research that seeks to improve outcomes in difficult-to-treat solid tumors while also expanding access to innovative cancer therapies.

A second major area of research at this hospital/clinic is Cardiovascular Diseases, with studies centered on heart failure. These trials are assessing whether new therapies can better lower the risk of cardiovascular death and hospital admission compared with usual care.

• Studies in chronic heart failure with reduced ejection fraction
• Research in heart failure with mildly reduced or preserved ejection fraction linked to systemic inflammation
• Trials evaluating new approaches to reduce cardiovascular death and heart failure hospitalization

This work shows a strong interest in improving long-term outcomes for people living with advanced heart failure, including patients who may have limited options with current treatments.

A substantial part of the research portfolio involves lung cancer, including metastatic non-small cell lung cancer, stage III lung cancer, and extensive-stage small cell lung cancer. The studies are mainly focused on testing new immunotherapy and targeted treatment strategies, often compared with standard chemotherapy or other established regimens.

• Research in advanced non-small cell lung cancer, including tumors with specific molecular features such as KRAS p.G12C
• Studies in small cell lung cancer aimed at improving overall survival
• Trials combining immunotherapy with other treatments to strengthen response and delay progression

These investigations reflect a strong effort to advance care for patients with aggressive thoracic cancers through more effective cancer treatment approaches.

The site also conducts important studies in melanoma and other high-risk skin cancers. The main goal is to determine whether newer immune-based therapies can better prevent recurrence after surgery and improve long-term disease-free outcomes.

• Trials in completely resected stage IIb/c melanoma examining ways to reduce recurrence
• Studies in resectable high-risk locally advanced cutaneous squamous cell carcinoma
• Research comparing adjuvant immunotherapy with placebo or standard care

This area of work is especially relevant for patients with earlier-stage disease where preventing relapse is a major treatment priority.